Inclusion Criteria:

- Pts with MG histologically confirmed at diagnosis, who were treated previously with
conventional external beam radiation & with or without chemotherapy, & have stable
disease, recurrence or relapse at the time of enrollment.

- Age > or = to 18 years.

- Patients who have had previous surgical resection(s) are eligible.

- Interval of at least 3 weeks between prior surgical resection, 2 weeks between prior
radiotherapy, or 4 weeks between prior chemotherapy, unless there is unequivocal
evidence of tumor progression after surgery, radiotherapy, or chemotherapy.

- Karnofsky performance score > or = to 60%.

- Adequate hematologic, renal & liver function as demonstrated by lab values performed
within 14 days, inclusive, prior to administration of chemotherapy:

- ANC > or = to 1500/mm3

- Platelet count > or = to 100,000/mm3

- Hemoglobin > or = to 10 gm/dL

- BUN and serum creatinine <1.5 times upper limit of lab normal

- Total serum bilirubin <1.5 times upper limit of lab normal

- SGOT <2.5 times upper limit of lab normal

- Patients must have recovered from any effects of major surgery.

- Patients must have life expectancy of greater than 12 weeks.

- Patients or legal guardian must give written, informed consent.

Exclusion Criteria:

- Patients requiring immediate radiation therapy.

- Patients who have not recovered from surgery.

- Patients who are not neurologically stable for 2 weeks prior to study entry.

- Patients who are poor medical risks because of non-malignant systemic disease as well
as those with acute infection treated with intravenous antibiotics.

- Frequent vomiting or medical condition that could interfere with oral medication
intake (e.g., partial bowel obstruction).

- Patient is < 5 years free of another primary malignancy except: if the other primary
malignancy is not currently clinically significant or requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
situ. Existence of any other malignant disease is not allowed.

- Known HIV positivity or AIDS-related illness.

- Pregnant or nursing women.

- Women of childbearing potential who are not using an effective method of
contraception. Women of childbearing potential must have a negative serum pregnancy
test 72 hours prior to administration of study drug and be practicing medically
approved contraceptive precautions.

- Men who are not advised to use an effective method of contraception.

- Patients taking immuno-suppressive agents other than prescribed corticosteroids.

- Patients previously treated with farnesyl transferase inhibitors.

- Patients with significant QTc prolongation (>500 msec)as evaluated by an EKG.

- Patients having presented prior disease progression on TEMODAR.

- Patients having presented any grade 4 hematologic toxicity or grade 3 or 4
non-hematologic toxicity on TEMODAR in the past.